ArticleCell metabolism2015
A Liver-Bone Endocrine Relay by IGFBP1 Promotes Osteoclastogenesis and Mediates FGF21-Induced Bone Resorption.
Article in Cell metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 157 citations in OpenAlex.
- Insulin like growth factor - insulin like growth factor binding protein family in osteoporosis: mechanistic and clinical insights.Annals of medicine · 2026Review
- The Liver-Bone Axis in Steatotic Liver Disease.Calcified tissue international · 2026Review
- Multifunctional scaffold inspired by hepatocyte exosomes promotes bone regeneration by regulating osteogenic differentiation via PI3K/AKT pathway.Materials today. Bio · 2026Article
- Medicine-food homologous bioactives in metabolic dysregulation-associated osteoporosis: a review of preclinical evidence and potential liver-bone and gut-bone actions.Chinese medicine · 2026Review
- The liver-bone axis: an emerging player in disease pathogenesis and therapeutic intervention.Science China. Life sciences · 2026Review
- Integrative Single-Cell Transcriptomic, Mendelian Randomization and In Silico Perturbation Analyses Prioritize MUC20 as a Candidate Gene Associated with Osteoporosis and Metabolic Dysfunction-Associated Steatotic Liver Disease in the Liver-Bone Axis.International journal of molecular sciences · 2026Article
- Association of fasting plasma glucagon with osteopenia/osteoporosis in Chinese patients with type 2 diabetes.BMC endocrine disorders · 2026Article
- Article
- Functional nucleic acid Hydrogels: Paving the way for Next-generation bone and cartilage regeneration.Materials today. Bio · 2026Review
- From algorithm to verification: based on network toxicology and machine learning, the immunomodulatory role of IGFBP1/MKI67/C9 in perfluorooctanoic acid-induced osteoarthritis was discovered, and a diagnostic model was constructed.Frontiers in immunology · 2026Article
- Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective.Journal of mammary gland biology and neoplasia · 2025Review
- Expression of pancreatic α-amylase and growth related genes during larval ontogeny in striped murrel (Channa striata).Scientific reports · 2025Article
- Exploring the Bone-Liver Axis: Impact of Acute Ethanol Intoxication on Post-Traumatic Liver Inflammation and Damage Following Femur Fracture.International journal of molecular sciences · 2025Article
- FGF-based drug discovery: advances and challenges.Nature reviews. Drug discovery · 2025Review
- Heart Failure and Osteoporosis: Shared Challenges in the Aging Population.Journal of cardiovascular development and disease · 2025Review
- Collagen supplementation and regenerative health: advances in biomarker detection and smart material integration.Frontiers in nutrition · 2025Review
- Roles of myokines in osteoporosis under physiological and diabetic conditions.Frontiers in endocrinology · 2025Review
- Wild-type bone marrow cells repopulate tissue resident macrophages and reverse the impacts of homozygous CSF1R mutation.PLoS genetics · 2025Article
- Extracellular derivatives for bone metabolism.Journal of advanced research · 2024Review
- Emerging role of liver-bone axis in osteoporosis.Journal of orthopaedic translation · 2024Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Fibroblast growth factor 21 (FGF21) promotes insulin sensitivity but causes bone loss. It elevates bone resorption by an undefined non-osteoclast-autonomous mechanism. We have detected a pro-osteoclastogenic activity in the hepatic secretome that is increased by FGF21 and largely attributed to insulin-like growth factor binding protein 1 (IGFBP1). Ex vivo osteoclast differentiation and in vivo bone resorption are both enhanced by recombinant IGFBP1 but suppressed by an IGFBP1-blocking antibody. Anti-IGFBP1 treatment attenuates ovariectomy-induced osteoporosis and abolishes FGF21-induced bone loss while maintaining its insulin-sensitizing metabolic benefit. Mechanistically, IGFBP1 functions via its RGD domain to bind to its receptor integrin β1 on osteoclast precursors, thereby potentiating RANKL-stimulated Erk-phosphorylation and NFATc1 activation. Consequently, osteoclastic integrin β1 deletion confers resistance to the resorption-enhancing effects of both IGFBP1 and FGF21. Therefore, the hepatokine IGFBP1 is a critical liver-bone hormonal relay that promotes osteoclastogenesis and bone resorption as well as an essential mediator of FGF21-induced bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.